Scientific Presentations at Society Meetings
To search publications using the available search words, please click here:
Reductions in low-density lipoprotein cholesterol and particle concentration and improvements in other parameters of dyslipidemia in a statin-treated patient with persistent dyslipidemia and high cardiovascular risk following switch from EPA+DHA (omega-3-acid ethyl esters) to high-purity EPA (icosapent ethyl)
Reduction in total ischemic events in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
Eicosapentaenoic acid reduces small dense low density lipoprotein oxidation and improves endothelial function in vitro as compared to other triglyceride-lowering agents [abstract].
Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with stage 3 chronic kidney disease and persistent high triglycerides
Effects of AMR101, a pure eicosapentaenoic omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study)
Reduction of revascularization in patients with hypertriglyceridemia with icosapent ethyl: insights from REDUCE-IT REVASC.
The triglyceride-lowering effects of icosapent ethyl (pure eicosapentaenoic acid ethyl ester) correlate with reductions in ASCVD risk factors commonly found in hypertriglyceridemic patients.
Eicosapentaenoic acid inhibited oxidized HDL-induced loss of endothelial nitric oxide release as compared to fenofibrate or niacin in vitro
Eicosapentaenoic acid, but not a mixed omega-3 fatty acid supplement, improved nitric oxide bioavailability in human endothelial cells in vitro.
Eicosapentaenoic acid (EPA) containing phospholipids modulate membrane structure.
REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups.
REDUCE-IT: Accumulation of data across prespecified interim analyses to final results.
Outcomes by baseline statin type.
Triglycerides, lesson from genetics.
Does high-dose fish oil reduce cardiovascular events via triglycerides?
Prevalence of hypertriglyceridaemia in statin treated very high-risk patients who might benefit from treatment with icosapent ethyl for secondary prevention in clinical practice–results of DYSIS.
Triglycerides 150 mg/dL and above are associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: a real-world analysis [abstract P739].
Eicosapentaenoic acid exposure lowers triglycerides without raising LDL-C by slowing TRL production and hastening LDL clearance in patients with residual triglyceridemia
Comparing eicosapentaenoic acid between plasma and serum from a randomized, controlled clinical trial
Effects of icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study)
Eicosapentaenoic acid is a strong predictor of risk for heart failure in the multi-ethnic study of atherosclerosis
Eicosapentaenoic acid inhibits oxidation of small dense LDL in a manner distinct from related fatty acids in vitro
The potential of electronic health record data to optimize recruitment efficiency in cardiovascular outcome trials
Predictive modeling to assess predictors of treatment success and failure among combination statin therapy patients
Managing the lipid triad: improving physicians' understanding of the role of omega-3 fatty acids with CME
Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention - insights from REDUCE-IT PCI.